Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 678

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 678
---
 since approval of new drug ____________ (*1)OSR Holdings’ ordinary shares issued for the purchase consideration transferred of ₩5,449,676,000 is 70,847shares at ₩76,922 per share. The number of OSR Holdings’ ordinary shares to be issued was determined based on negotiation with the former owners of RMC. (*2)Purchase consideration reflects the value of (i) 696,225 OSR Holdings ordinary shares issued to BCME, (ii) 1,750 BCME preferred shares assigned to BCME by OSR Holdings, and (iii) US$3,600,000. The per share value of the OSR Holdings ordinary shares and BCME preferred shares was ₩163,046 and ₩3,782,199, respectively. The purchase consideration was determined based on negotiations between OSR Holdings and BCME. 33.3 Patent technology from business combination Details of patent technology recognized from the acquisition of Darnatein that occurred for the year ended December 31, 2023 are set forth in the table below.

| (Korean won in thousand)        |     | Amount          |
| Patent technology project code: |     |                 |
| DRT 101                         |     | ₩    94,788,203 |

(1) DRT-101 DRT -101is a synthetic bio -signalingmolecule that replaces BMPRII -bindingsegments of BMP -7, one of the bone -formingproteins, with high affinity ActRII binding segments of Activin A, a member of the transforming growth factor ß (TGF -ß) superfamily along with BMP -7. In nature, endogenous BMP7 promotes chondrogenesis in damaged cartilage tissue by signaling primarily via the type II receptor BMPRII and to a lesser extent via the activin type II receptor ActRII, which it binds with lower affinity. DRT -101amplifies intracellular regeneration signaling capacity compared to natural BMP -7and allows for regeneration and restoration of mechanically depleted cartilage cells to normal levels. Osteoarthritis is the most common joint disorder in the aging population. Although surgical treatment of osteoarthritis can reduce pain and improve joint mobility and function, the operative management of osteoarthritis is associated with significant cost and morbidity. Unmet medical needs for DRT -101for Osteoarthritis are enormous specially with aging population. Unique market